APSR2026-1032

 
Late-Breaking
Submitted
Oral Presentation
AO30-007
 
 
https://storage.unitedwebnetwork.com/files/1285/1245190-46903-Hsia Tzu Lan-30th APRS congress oral presentation_434494.pptx
Format: PPTX Only
 
Format: PDF Only
16. Interstitial Lung Disease
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Tzu-Lan Hsia * National Yang Ming Chiao Tung University Department of Biotechnology and Laboratory Science in Medicine Taipei City Taiwan
Wei-Chung Chiou - National Yang Ming Chiao Tung University Department of Biotechnology and Laboratory Science in Medicine Taipei City Taiwan
Kuo-Chuan Chen - Titan Biological & Agriculture Technology Co. Ltd. CEO & Founder Wanchai Hong Kong
Pin-Kuei Fu - Taichung Veterans General Hospital Integrated Care Center of Interstitial Lung Disease Taichung City Taiwan
Cheng Huang - National Yang Ming Chiao Tung University Department of Biotechnology and Laboratory Science in Medicine Taipei City Taiwan
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Tzu-Lan
Hsia
karta2969922@gmail.com
+886958670713
Under 30
Taiwan
Original Research
Ganoderma microsporum immunomodulatory protein ameliorates pulmonary fibrosis through modulation of VEGFR2 phosphorylation and autophagy signaling
Maximum 25 words
Abstract Content
Idiopathic pulmonary fibrosis (IPF) is a progressive and frequently fatal lung disease for which only a limited number of United States Food and Drug Administration (FDA)-approved therapies are available. Ganoderma microsporum immunomodulatory protein (GMI) is a recombinant fungal protein with potent anti-inflammatory properties, but its role in pulmonary fibrosis remains unclear. This study evaluated the therapeutic efficacy of GMI in bleomycin (BLM)-induced mice and investigated its molecular mechanisms in human lung fibroblasts.
C57BL/6J mice were administered intratracheal BLM and treated orally with GMI or Pirfenidone from day 1 to 21. Fibrosis was assessed via micro-computed tomography (μCT), histology, and bronchoalveolar lavage fluid (BALF) analysis. In vitro, human lung fibroblasts (LL29) were stimulated with transforming growth factor-beta 1 (TGF-β1) and treated with GMI to evaluate migration, invasion, and signaling pathways.
In BLM-induced mice, GMI significantly improved survival rates, attenuated body weight loss, and reduced lung weight-to-body weight ratios. GMI markedly reduced lung injury, inflammatory cell infiltration, and cytokine production, including TGF-β1, TNF-α, IL-1β, and IL-6, in bronchoalveolar lavage fluid. Furthermore, GMI decreased collagen deposition, Ashcroft scores, and the expression of the myofibroblast markers α-SMA, COL1A1, and fibronectin. In TGF-β1-induced LL29 cells, GMI inhibited TGF-β1-induced fibroblast migration and invasion without causing cytotoxicity. Mechanistically, GMI downregulated p-ERK, p-JNK, and p-p38 expression, as well as PI3K/Akt/mTOR signaling, and restored autophagic flux by up-regulating p-ULK1, Beclin-1, and LC3BII while reducing p62. Notably, receptor tyrosine kinase array and co-immunoprecipitation revealed that GMI interacted with vascular endothelial growth factor receptor 2 (VEGFR2), selectively suppressing its phosphorylation and downstream signaling.
GMI ameliorates BLM-induced pulmonary fibrosis and halts myofibroblast activation by inhibiting VEGFR2 phosphorylation, suppressing downstream signaling, and restoring autophagic flux. These findings suggest that GMI represents a promising therapeutic candidate for pulmonary fibrosis.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Idiopathic pulmonary fibrosis, Ganoderma microsporum immunomodulatory protein, Vascular endothelial growth factor receptor 2
maximum 3 keywords and no abbreviations, separated by commas
 
294